|
1 Indications And Usage Imatinib Mesylate Is A Kinase Inhibitor Indicated For The Treatment Of: • Newly Diagnosed Adult And Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ Cml) In Chronic Phase ( 1.1 ) • Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ Cml) In Blast Crisis (Bc), Accelerated Phase (Ap), Or In Chronic Phase (Cp) After Failure Of Interferon-Alpha Therapy ( 1.2 ) • Adult Patients With Relapsed Or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ All) ( 1.3 ) • Adult Patients With Myelodysplastic/myeloproliferative Diseases (Mds/mpd) Associated With Pdgfr (Platelet-Derived Growth Factor Receptor) Gene Re-Arrangements As Determined With An Fda-Approved Test ( 1.5 ) • Adult Patients With Aggressive Systemic Mastocytosis (Asm) Without The D816v C-Kit Mutation As Determined With An Fda-Approved Test Or With C-Kit Mutational Status Unknown ( 1.6 ) • Adult Patients With Hypereosinophilic Syndrome (Hes) And/or Chronic Eosinophilic Leukemia (Cel) Who Have The Fip1l1-Pdgfrα Fusion Kinase (Mutational Analysis Or Fish Demonstration Of Chic2 Allele Deletion) And For Patients With Hes And/or Cel Who Are Fip1l1-Pdgfrα Fusion Kinase Negative Or Unknown ( 1.7 ) • Adult Patients With Unresectable, Recurrent And/or Metastatic Dermatofibrosarcoma Protuberans (Dfsp) ( 1.8 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ Cml) Newly Diagnosed Adult And Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ Cml) In Chronic Phase. 1.2 Ph+ Cml In Blast Crisis (Bc), Accelerated Phase (Ap) Or Chronic Phase (Cp) After Interferon-Alpha (Ifn) Therapy Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia In Blast Crisis, Accelerated Phase, Or In Chronic Phase After Failure Of Interferon-Alpha Therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (All) Adult Patients With Relapsed Or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ All). 1.5 Myelodysplastic/myeloproliferative Diseases (Mds/mpd) Adult Patients With Myelodysplastic/myeloproliferative Diseases Associated With Pdgfr (Platelet-Derived Growth Factor Receptor) Gene Re-Arrangements As Determined With An Fda-Approved Test [See Dosage And Administration ( 2.6 )] . 1.6 Aggressive Systemic Mastocytosis (Asm) Adult Patients With Aggressive Systemic Mastocytosis Without The D816v C-Kit Mutation As Determined With An Fda-Approved Test [See Dosage And Administration ( 2.7 )] Or With C-Kit Mutational Status Unknown. 1.7 Hypereosinophilic Syndrome (Hes) And/or Chronic Eosinophilic Leukemia (Cel) Adult Patients With Hypereosinophilic Syndrome And/or Chronic Eosinophilic Leukemia Who Have The Fip1l1-Pdgfrα Fusion Kinase (Mutational Analysis Or Fish Demonstration Of Chic2 Allele Deletion) And For Patients With Hes And/or Cel Who Are Fip1l1-Pdgfrα Fusion Kinase Negative Or Unknown. 1.8 Dermatofibrosarcoma Protuberans (Dfsp) Adult Patients With Unresectable, Recurrent And/or Metastatic Dermatofibrosarcoma Protuberans.
|